“Brodalumab, a Human Anti-Interleukin-17 Receptor A Monoclonal Antibody, Shows Low Immunogenicity in Patients with Moderate-to-Severe Psoriasis” (2018) SKIN The Journal of Cutaneous Medicine, 2(S1), p. S1. doi:10.25251/skin.2.supp.1.